Skip to Content

Hartford Healthcare R5 HGHTX

Medalist Rating as of | See Hartford Funds Investment Hub
  • NAV / 1-Day Return 44.68  /  −0.13 %
  • Total Assets 1.1 Bil
  • Adj. Expense Ratio
    1.020%
  • Expense Ratio 1.020%
  • Distribution Fee Level High
  • Share Class Type Retirement, Large
  • Category Health
  • Investment Style Large Growth
  • Min. Initial Investment
  • Status Open
  • TTM Yield
  • Turnover 32%

USD | NAV as of Apr 16, 2024 | 1-Day Return as of Apr 16, 2024, 10:15 PM GMT+0

Morningstar’s Analysis HGHTX

Will HGHTX outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

Hartford Healthcare Loses a Manager; Ratings Unchanged

null Andrew Redden

Andrew Redden

Analyst Note

Fayyaz Mujtaba is leaving Wellington Management, the sole subadvisor of Hartford Healthcare, and will no longer serve as a manager of this strategy, effective immediately. His departure does not affect the strategy’s Above Average People rating or its Morningstar Medalist Rating of Silver or Bronze, depending on share class.

Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings HGHTX

  • Current Portfolio Date
  • Equity Holdings
  • Bond Holdings
  • Other Holdings
  • % Assets in Top 10 Holdings 43.3
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Eli Lilly and Co

10.89 128.1 Mil
Healthcare

UnitedHealth Group Inc

6.78 79.8 Mil
Healthcare

Merck & Co Inc

6.35 74.6 Mil
Healthcare

Danaher Corp

3.90 45.9 Mil
Healthcare

Stryker Corp

2.83 33.3 Mil
Healthcare

Boston Scientific Corp

2.80 32.9 Mil
Healthcare

Thermo Fisher Scientific Inc

2.52 29.7 Mil
Healthcare

HCA Healthcare Inc

2.52 29.7 Mil
Healthcare

AbbVie Inc

2.39 28.1 Mil
Healthcare

Vertex Pharmaceuticals Inc

2.32 27.3 Mil
Healthcare